SCHEMBL24076911

SCHEMBL24076911

CC(=O)c1ccc2c(=O)[nH]nc(C(C)C)c2c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.48
▸ SLC2A1 P11166 1/20 0.44
▸ TSHR P16473 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.40
▸ HPGD P15428 3/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ KIF11 P52732 1/20 0.38
▸ NCOA1 Q15788 1/20 0.38
▸ NCOA3 Q9Y6Q9 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ KMT2A Q03164 2/20 0.37
▸ ALPL P05186 1/20 0.37
▸ ALPI P09923 1/20 0.37
▸ ALPG P10696 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24076882 0.81 POLB (0.41) POLBTSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL24076910 0.78 TSHR (0.51) POLBTSHRALDH1A1HPGDSMN1; SMN2
SCHEMBL24076266 0.77 POLB (0.44) POLBTSHRALDH1A1SMN1; SMN2NPC1
SCHEMBL30452337 0.77 POLB (0.44) POLBTSHRALDH1A1SMN1; SMN2NPC1
SCHEMBL22552265 0.77 POLB (0.44) POLBTSHRALDH1A1SMN1; SMN2CYP1A2
SCHEMBL24076885 0.75 POLB (0.43) POLBTSHRSMN1; SMN2CYP1A2NPC1
SCHEMBL24076279 0.75 POLB (0.42) POLBTSHRALDH1A1SMN1; SMN2CYP1A2
SCHEMBL24076922 0.75 POLB (0.42) POLBTSHR
SCHEMBL24076915 0.75 DYRK1A (0.46) POLBTSHRMAPTKDM4E
SCHEMBL30231242 0.75 DYRK1A (0.46) POLBTSHRMAPTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
US-20230202989-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 — — US disclosed
WO-2021239885-A1 COMPOUNDS JANSSEN PHARMACEUTICA NV (BE) 2021-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230202989-A1 COMPOUNDS NLRP3, NLRP1, IL1B POLB 3231/4885SLC2A1 4498/4885TSHR 4236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback